1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Baudax Bio, Inc.

Baudax Bio, Inc.

BXRXQ
Baudax Bio, Inc.US flagOther OTC
0.00
USD
- -
- -
4,359.00Market Cap
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
TTM
Revenue per Share
- -
- -
- -
37.03
19.73
3.83
0.08
Basic EPS, GAAP
-9,420.73
-11,361.35
-4,875.26
-5,715.36
-405.41
-177.3
-1.79
Free Cash Flow per Basic Share
-6,872.15
-9,747.53
-7,716.08
-3,356.89
-903.83
-83.87
-3.59
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
- -
- -
-5,409.7
-8,399.02
-2,413.14
-575.63
-47.44
Tangible Book Value per Share
-14,032.08
-14,940.47
-6,775.68
-3,092.75
-193.27
-79.52
-5.75
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
4
Sales/Revenue/Turnover
- -
- -
- -
- -
1
1
- -
Operating Margin (%)
- -
- -
- -
-11,319.88
-4,849.63
-2,816.63
-7,076.45
Depreciation Expense
- -
- -
- -
3
3
2
- -
Net Income, GAAP
-61
-74
-33
-76
-20
-59
-7
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
- -
-15,436.11
-1,830.46
-4,633.18
-2,308.06
Working Capital
-42
-20
12
19
8
-15
-18
LT Debt
- -
- -
- -
8
6
2
3
Total Equity
-62
-68
-17
-15
13
-24
-10
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
Mar'23
Jun'23
Sep'23
ST Debt
6
6
6
LT Borrowings
1
- -
- -
LT Finance Leases
- -
2
3
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
3
7
12
Market Capitalization
- -
- -
- -

Working Capital

FRC

•

in mil. unless spec.
Mar'23
Jun'23
Sep'23
Total Current Assets
4
2
1
Cash, Cash Equivalents & STI
4
1
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
12
20
19
Payables & Accruals
6
8
11
ST Debt
6
6
6
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-110.05%
-283.29%
Free Cash Flow
- -
-4.6%
-43.78%
Net Income, GAAP
- -
44.38%
197.41%
Sales/Revenue/Turnover
- -
- -
17.5%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
- -
- -
- -
- -
1
2022
- -
- -
- -
- -
1
2023
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
-378.33
-286.9
-281.36
486.26
-405.41
2022
-79.89
-41.95
-98.7
-12.33
-177.3
2023
4.91
-1.51
-0.24
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -

Company Description

APIChat
CEO
Geraldine A. Henwood
Full Time Employees
9
Sector
Healthcare
Industry
Biotechnology
Address
490 Lapp Road Malvern PA United States of America 19355
IPO Date
Feb 21, 2024
CIK
0001780097
Website
baudaxbio.com
Similar Companies
20/20 GeneSystems Inc. (TWTG)
Nicox S.A. (COX.PA)
Reviva Pharmaceuticals Holdings, Inc. (RVPHW)
Soligenix Inc. Warrant (SNGXW)
SQZ Biotechnologies Company (SQZB)
Immix Biopharma, Inc. (IMMX)
Business
Baudax Bio, Inc. (BXRXQ) develops and commercializes innovative products for acute care settings, focusing on neuromuscular blocking agents and anticoagulants; its core offerings include ANJESO (meloxicam injection), a proprietary non-opioid analgesic for moderate-to-severe pain administered via once-daily subcutaneous or intravenous routes; and other pipeline candidates targeting hospital-based therapeutic needs such as reversal agents and novel injectable therapies. The company operates in the biopharmaceutical industry, primarily serving healthcare providers, hospitals, and patients in the United States, with research, development, and commercialization activities centered domestically. Founded in 2019 as a spin-off from West Pharmaceutical Services, Inc., Baudax Bio maintains its headquarters in Malvern, Pennsylvania. In recent developments within the last two years, Baudax Bio has undergone significant financial restructuring, including a Chapter 11 bankruptcy filing in 2023 amid challenges with commercialization efforts and capital needs, leading to delisting from NASDAQ and trading over-the-counter under BXRXQ; this process culminated in substantial debt reduction and operational streamlining to support ongoing product development. The company has not announced major new partnerships, acquisitions, or product launches since early 2023, instead prioritizing pipeline advancement for its neuromuscular and pain management portfolio amid a strategic shift toward sustainable growth post-restructuring. No subsidiaries or parent relationships are currently active following the spin-off origins.